Markets

Silence Therapeutics plc (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) therapies, today announced that it has commenced an underwritten public offering of…

New Funding Further Solidifies Point2’s e‑Tube Technology Platform as the Foundation for Next-Generation AI Data-Center Interconnect

Enterprise AI SaaS leader to accelerate Brightfin's AI-Native platform for IT financial management

Harbor Deploy is the first AI deployment offering built exclusively for law firms and corporate legal departments, bringing the embedded-engineering model now reshaping enterprise AI to the industry where confidentiality,…

AT&T customers at Mississippi State University’s Davis Wade Stadium in Starkville are getting a boost in wireless connectivity following the deployment of a new AT&T-led distributed antenna system, or DAS,…

Trial met its primary endpoint, with a significantly higher proportion of clinical responders on divesiran (88%) compared to placebo (19%); placebo-adjusted response rate = 69% Both divesiran dose groups showed…

Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30,…

Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a conference call and webcast to discuss topline results from the Phase…

Dejero, ADLINK Technology, Eutelsat and Intel among the sponsors powering the first-ever livestream of North America's only tarmac rally, with a live demonstration at IBC and a video message from…

Gleklen, who invests in AI-application companies, joins new principal Jason Mendel and eight other investors globally promoted to new roles